环丙烷羰基溴化物 | 20905-31-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 环丙烷羰基溴化物
• 英文名称: Cyclopropylcarbonylbromid
• 英文别名: cyclopropanecarbonyl bromide；Cyclopropancarbonylbromid
• CAS: 20905-31-1
• 化学式: C₄H₅BrO
• 分子量: 148.987
• InChiKey: ZXNUWRQNUJSWSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2916209090

反应信息

• 作为反应物：
  描述：

  环丙烷羰基溴化物 在 二叔丁基过氧化物 、 六正丁基二锡 作用下， 以 二氯二氟甲烷 为溶剂， 生成 cyclopropylacyl
  参考文献：
  名称：

  Davies, Alwyn G.; Sutcliffe, Roger, Journal of the Chemical Society. Perkin transactions II, 1982, p. 1483 - 1488

  摘要：

  DOI：
• 作为产物：
  描述：

  环丙甲酸 在 三溴化磷 作用下， 反应 1.0h， 以25%的产率得到环丙烷羰基溴化物
  参考文献：
  名称：

  Davies, Alwyn G.; Sutcliffe, Roger, Journal of the Chemical Society. Perkin transactions II, 1982, p. 1483 - 1488

  摘要：

  DOI：

文献信息

• [EN] N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA<br/>[FR] DÉRIVÉS DE N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE ET DE N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS D'IRAK4 POUR LE TRAITEMENT DE L'ASTHME
  申请人：ASTRAZENECA AB

  公开号：WO2022122876A1

  公开（公告）日：2022-06-16

  The present application relates to a compound of Formula (A),wherein R1 is selected from Formula (II) and Formula (III) and R2 is selected from Formula (IV), Formula (V) and Formula (VI) as IRAK4 inhibitors for use in methods of treatment of e.g. asthma and chronic obstructive pulmonary disease (COPD), cancer, inflammatory diseases, and autoinflammatory/autoimmune diseases such as e.g. systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjogren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis. Preferred compounds of the present invention are e.g.: • N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2H-indazole-5- carboxamide, • N-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2H-indazole-5- carboxamide, • N-(imidazo[1,2-b]pyridazin-3-yl)-1-azaspiro[4.5]decan-8-yl-2H- indazole-5-carboxamide, and • N-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-azaspiro[4.5]decan-8-yl-2H- indazole-5-carboxamide derivatives. An exemplary compound of the present invention is e.g. N- (imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-((5r,8r)-1-methyl-2-oxo-1- azaspiro[4.5]decan-8-yl)-2H-indazole-5-carboxamide (Example 1): Formula (VII).

  本申请涉及一种化合物，其化学式为(A)，其中R1从化学式(II)和化学式(III)中选择，R2从化学式(IV)、化学式(V)和化学式(VI)中选择，作为IRAK4抑制剂用于治疗哮喘和慢性阻塞性肺疾病(COPD)、癌症、炎症性疾病以及自身免疫性疾病，如系统性红斑狼疮、类风湿性关节炎、肌炎、干燥综合症、系统性硬化症、痛风、子宫内膜异位症和银屑病等。本发明的优选化合物包括：•N-(咪唑并[1,2-b]吡嗪-3-基)-1-环己基-2H-吲唑-5-羧酰胺、•N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-羧酰胺、•N-(咪唑并[1,2-b]吡嗪-3-基)-1-氮杂螺[4.5]癸烷-8-基-2H-吲唑-5-羧酰胺和•N-(吡唑并[1,5-a]嘧啶-3-基)-1-氮杂螺[4.5]癸烷-8-基-2H-吲唑-5-羧酰胺衍生物。本发明的一种示例化合物是N-(咪唑并[1,2-b]吡嗪-3-基)-6-甲氧基-2-((5r,8r)-1-甲基-2-氧代-1-氮杂螺[4.5]癸烷-8-基)-2H-吲唑-5-羧酰胺(实例1)：化学式(VII)。
• Recognition memory for source and occurrence: The importance of recollection
  作者：Joel R. Quamme、Christina Frederick、Neal E. A. Kroll、Andrew P. Yonelinas、Ian G. Dobbins

  DOI：10.3758/bf03195775

  日期：2002.9

  Previous recognition memory studies indicate that when both recollection and familiarity are expected to contribute to recognition performance (e.g., discriminating studied items from nonstudied items) the dual-process and the unequal-variance signal detection models provide comparable accounts of performance. When familiarity is not expected to be useful (e.g., when items from two equally familiar sources are discriminated between), the dual-process model provides a significantly better account of performance. In the present study, source recognition was tested under conditions in which familiarity could have been used to perform a list-discrimination task; participants were required to discriminate between strong studied items, weak studied items, and new items., The dual-process model provided a better account of performance than did the unequal-variance model. Moreover, the results indicated that the unequal-variance assumption in a single-process signal detection model was not a valid substitution for recollection and that recollection was used to make recognition judgments even when assessments of familiarity were useful.
• Davies, Alwyn G.; Sutcliffe, Roger, Journal of the Chemical Society. Perkin transactions II, 1982, p. 1483 - 1488
  作者：Davies, Alwyn G.、Sutcliffe, Roger

  DOI：——

  日期：——